Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;79(6):886-95.
doi: 10.1111/bcp.12591.

Therapeutic antibodies against CGRP or its receptor

Marcelo E Bigal  1   2 , Sarah Walter  3 , Alan M Rapoport  4   5
Affiliations
Review

Therapeutic antibodies against CGRP or its receptor

Marcelo E Bigal et al. Br J Clin Pharmacol. 2015 Jun.

Abstract

CGRP is an extensively studied neuropeptide that has been implicated in the pathophysiology of migraine. While a number of small molecule antagonists against the CGRP receptor have demonstrated that targeting this pathway is a valid and effective way of treating migraine, off-target hepatoxicity and formulation issues have hampered the development for regulatory approval of any therapeutic in this class. The development of monoclonal antibodies to CGRP or its receptor as therapeutic agents has allowed this pathway to be re-investigated. Herein we review why CGRP is an ideal target for the prevention of migraine and describe four monoclonal antibodies against either CGRP or its receptor that are in clinical development for the treatment of both episodic and chronic migraine. We describe what has been publically disclosed about their clinical trials and future clinical development plans.

Keywords: CGRP; chronic migraine; migraine; monoclonal antibodies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Haemodynamic data from a 14 week, repeat dose study of TEV-48125 (LBR-101) in monkeys. Data are shown with 95% confidence intervals. A: systolic blood pressure; B: diastolic blood pressure; C: heart rate; D: time–concentration profile at weeks 1 and 13. Modified from reference . Vehicle, 10 mg kg–1, 100 mg kg–1, 300 mg kg–1. Week 1 10 mg kg–1, 100 mg kg–1, 300 mg kg–1, Week 13 10 mg kg–1, 100 mg kg–1, 300 mg kg–1
Figure 2
Figure 2
Cardiovascular parameters in subjects receiving TEV-48125 (LBR-10) or placebo. Footnote: Data from phase 1 study of TEV-48125 in normal, healthy women volunteers. TEV-48125 or placebo was delivered as a 1 h i.v. infusion. Means are shown ± SD. placebo, LBR-10
See this image and copyright information in PMC

References

    1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med. 2002;346:257–70. - PubMed
    1. Headache Classification Subcommittee of the International Headache S. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160. - PubMed
    1. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58:885–94. - PubMed
    1. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559–66. - PubMed
    1. Di Clemente L, Coppola G, Magis D, Fumal A, De Pasqua V, Di Piero V, Schoenen J. Interictal habituation deficit of the nociceptive blink reflex: an endophenotypic marker for presymptomatic migraine? Brain. 2007;130:765–70. - PubMed

MeSH terms

Substances